Abstract Library

#4579 Real-world effectiveness of lanreotide autogel in patients with advanced gastroenteropancreatic neuroendocrine tumours with antigen Ki-67 proliferation index above and below 10%: The KINETICS study

Introduction: The somatostatin analogue lanreotide is an established treatment option for patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) with a Ki-67 proliferation index (Ki-67)

Conference:

Presenting Author: Vandamme T

Authors: Vandamme T, Gerard L, Del Olmo-Garcia M, de Mestier L, Kiesewetter B,

Keywords: effectiveness, gastroenteropancreatic neuroendocrine tumour, GEP-NET, Ki-67 proliferation index, Ki-67, lanreotide, somatostatin analogue, somatostatin, real-world,

#4551 Characterisation and management of neuroendocrine tumours: Findings from a prospective study in Algeria

Introduction: Gastrointestinal neuroendocrine tumours are characterised by varied clinical presentations and behaviours. Their increasing incidence highlights the need for better understanding and management strategies.

Conference:

Presenting Author:

Authors: Zerrouk D, Boukerzaza I, Laouar N, Kassama Z, Mansouri F,

Keywords: Neuroendocrine neoplasm, Observational Study, Treatment Outcomes,

#4499 Impact of early molecular tumour board inclusion on treatment outcomes in neuroendocrine neoplasms: A retrospective double-centre study

Introduction: The treatment of neuroendocrine neoplasms (NENs) is particularly challenging due to the limited availability of standard therapies. While personalised approaches are revolutionising many areas of oncology, their progress in the field of NENs has been comparatively slower. The integration of molecular tumour boards (MTBs) into clinical practice represents a major advance in oncology, even for rare entities such as NENs.

Conference:

Presenting Author: Klaas L

Authors: Barsch M, Graessel L, Metzger P, Klaas L, Schulz L,

Keywords: Neuroendocrine neoplasm, Molecular Tumour Board, personalised medicine, precision oncology, targeted therapy,

#4437 Pancreatic metastases in neuroendocrine neoplasia: A systematic review

Introduction: Neuroendocrine neoplasias (NENs) are a heterogeneous group of neoplasms that often metastasise to distant organs, with the liver and bones as common targets. However, metastases to the pancreas are uncommon, accounting for 2–5% of pancreatic malignancies.

Conference:

Presenting Author:

Authors: Rinzivillo M, Romano E, Dell' Unto E, Marasco M, Panzuto F,

Keywords: pancreatic metastasis, 68Gallium-PET, incidence,

#4382 Sensitivity of endoscopic ultrasound in detecting small gastrointestinal neuroendocrine tumours

Introduction: Small gastrointestinal neuroendocrine tumours (GI-NETs) are often difficult to detect using conventional imaging modalities, leading to delayed diagnosis and suboptimal treatment outcomes. Endoscopic ultrasound (EUS) has emerged as a promising tool for the early detection and precise localisation of these tumours. However, its sensitivity in identifying small lesions remains to be thoroughly evaluated.

Conference:

Presenting Author:

Authors: Xu L, Ye M, Xue B, Tang Q,

Keywords: Endoscopic ultrasound, small gastrointestinal neuroendocrine tumour, early detection, imaging modalities,